Abbott's second-quarter Diagnostics segment posted 42.3% reported sales growth, but comparable growth came in at just 2.9%. The gap stems from the March 23 acquisition of Exact Sciences, which added its Cancer Diagnostics business to Abbott's portfolio. U.S. Diagnostics sales surged 104.8% on a reported basis, yet comparable growth was 4.0%. The Cancer Diagnostics unit, built around Cologuard colorectal screening tests, grew 13.3% on a comparable basis, driven by what the company describes as a growing base of new and repeat users
This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.
(END) Dow Jones Newswires
July 16, 2026 08:19 ET (12:19 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.